CompletedPhase 3

The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

China332 participantsStarted 2021-12-30

Plain-language summary

To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female subjects aged 18-75 years (inclusive);
✓. Subjects with a confirmed diagnosis of reflux esophagitis (Grade A-D according to LA classification) by esophagogastroduodenoscopy (EGD) at our site within 7 days prior to Visit 2 (date of randomization).
✓. Able to understand the information provided and to comply with protocol requirements;
✓. Voluntarily agreed to participate in this clinical study and signed the informed consent form (ICF).

What they're measuring

mucosal healing within 8 weeks

Timeframe: 8weeks

Trial details

NCT IDNCT05813561

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-07-23

View on ClinicalTrials.gov More Reflux Esophagitis trials